Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli mężczyźni z zaawansowanym rakiem prostaty opornym na leczenie hormonalne, którzy rozpoczynają leczenie lutetem 177Lu
- •Wiek co najmniej 18 lat
- •Pisemna zgodę na udział w badaniu
- •Gotowość do wypełniania ankiet o jakości życia przez 1 rok od rozpoczęcia leczenia
✗ Disqualifies
- •Jednoczesny udział w innym badaniu klinicznym lub innym badaniu firmy Novartis z użyciem tego samego leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 13, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (38)
Novartis Investigative Site
Konstanz, Germany
Novartis Investigative Site
Stuttgart, Germany
Novartis Investigative Site
Munich, Germany
Novartis Investigative Site
Regensburg, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Cottbus, Germany
Novartis Investigative Site
Frankfurt (Oder), Germany
Novartis Investigative Site
Ludwigshafen, Germany
Novartis Investigative Site
Marburg, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Leipzig, Germany
Novartis Investigative Site
Halle, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bielefeld, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Braunschweig, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Dortmund, Germany
Novartis Investigative Site
Dortmund, Germany
Novartis Investigative Site
Erfurt, Germany
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Fulda, Germany
Novartis Investigative Site
Herford, Germany
Novartis Investigative Site
Homburg, Germany
Novartis Investigative Site
Magdeburg, Germany
Novartis Investigative Site
Mainz, Germany
Novartis Investigative Site
Nuremberg, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Trier, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Ulm, Germany
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.